v3.26.1
Acquisitions - Preliminaty Purchase Price Allocation (Details) - USD ($)
$ in Millions
Jun. 30, 2026
May 14, 2026
Dec. 31, 2025
Business Combination [Line Items]      
Goodwill $ 6,990.8   $ 6,491.1
Apellis Pharmaceuticals, Inc.      
Business Combination [Line Items]      
Cash and cash equivalents   $ 310.7  
Accounts receivable   384.4  
Inventory   712.0  
Other current assets   46.1  
Accounts payable   (32.9)  
Accrued expense and other   (117.4)  
Senior secured term loan   (395.2)  
Convertible note   (101.5)  
Operating lease liabilities   (18.1)  
Total identifiable net assets   4,908.6  
Goodwill   501.5  
Total assets acquired and liabilities assumed   5,410.1  
Apellis Pharmaceuticals, Inc. | Deferred tax liability      
Business Combination [Line Items]      
Notes payable   (522.1)  
Apellis Pharmaceuticals, Inc. | Other, net      
Business Combination [Line Items]      
Notes payable   0.1  
Apellis Pharmaceuticals, Inc. | Completed Technology      
Business Combination [Line Items]      
Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived   4,630.0  
Apellis Pharmaceuticals, Inc. | EMPAVELI | Completed Technology      
Business Combination [Line Items]      
Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived   2,400.0  
Apellis Pharmaceuticals, Inc. | SYFOVRE | Completed Technology      
Business Combination [Line Items]      
Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived   1,900.0  
Apellis Pharmaceuticals, Inc. | Pegcetacoplan | In-process research and development      
Business Combination [Line Items]      
Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived   $ 12.5